<DOC>
	<DOCNO>NCT00459121</DOCNO>
	<brief_summary>RATIONALE : Vandetanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving vandetanib together chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give vandetanib together carboplatin paclitaxel work treat patient stage I , stage II , stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Vandetanib , Carboplatin , Paclitaxel Treating Patients With Stage I , Stage II , Stage III Non-Small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility neoadjuvant vandetanib combination carboplatin paclitaxel patient resectable stage IB , II , IIIA non-small cell lung cancer . Secondary - Assess 30-day postoperative mortality rate patient . - Assess toxicity regimen patient . - Determine percentage patient complete plan course therapy . - Assess clinical response rate patient treat regimen . - Assess pathologic complete response rate patient treat regimen . OUTLINE : This multicenter study . Patients receive oral vandetanib daily day 1-21 . Patients also receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 . Treatment repeat every 3 week 3 course . Patients undergo surgery least 3 week last course chemotherapy . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , meet 1 follow stag criterion : Stage IB II disease T3 , N01 disease ( stage IIIA ) Deemed surgical candidate No prior lung cancer ( NSCLC small cell lung cancer ) PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence severe uncontrolled systemic disease concurrent condition , opinion investigator , would preclude study compliance No peripheral neuropathy ≥ grade 2 No hemoptysis within past 12 week No spontaneous bleed within past 12 week No clinically significant cardiac event ( e.g. , NYHA class IIIV heart disease , myocardial infarction ) within past 3 month No history asymptomatic sustain ventricular tachycardia arrhythmia symptomatic require treatment , include follow : Multifocal premature ventricular contraction Bigeminy Trigeminy Ventricular tachycardia Uncontrolled atrial fibrillation Atrial fibrillation control medication allow No history QTc prolongation result medication require discontinuation medication No congenital long QT syndrome firstdegree family relative unexplained death age 40 No leave bundle branch block No QTc Bazett 's correction unmeasurable QTc ≥ 480 millisecond screen ECG Patients QTc ≥ 480 millisecond screen ECG may ECG repeat twice Average QTc 3 screen ECG 's must &lt; 480 millisecond No uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) No active diarrhea active gastrointestinal disease may affect absorption study drug ability tolerate study drug No malignancy within past 3 year except situ cervical carcinoma adequately treat basal cell squamous cell carcinoma skin PRIOR CONCURRENT THERAPY : More 4 week since major surgery recover No prior carboplatin , paclitaxel , vandetanib More 30 day since prior investigational agent More 2 week since prior concurrent drug induce CYP3A4 include , limited , follow : Rifampin Phenytoin Carbamazepine Barbiturates Hypericum perforatum ( St. John 's wort ) No medication may cause QTc prolongation induce torsades de point 2 week prior begin study treatment , , 2 week completion study treatment No concurrent combination antiretroviral treatment HIVpositive patient No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>